PDGFRB and neoplasm: We noted that in the subcutaneous tumor model, both the anti-PDGF-BB antibodies and PDGFR inhibitor STI571 significantly inhibited tumor growth in the CAF co-injection group, reducing the tumor size and weight to the same levels as in the tumor cell-only injection group.